Orally Active, Nonpeptide Vasopressin V<sub>2</sub> Receptor Antagonists: A Novel Series of 1-[4-(Benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1<i>H</i>-benzazepines and Related Compounds
作者:Hidenori Ogawa、Hiroshi Yamashita、Kazumi Kondo、Yoshitaka Yamamura、Hisashi Miyamoto、Keizo Kan、Kazuyoshi Kitano、Michinori Tanaka、Kenji Nakaya、Shigeki Nakamura、Toyoki Mori、Michiaki Tominaga、Youichi Yabuuchi
DOI:10.1021/jm960133o
日期:1996.1.1
This paper describes a novel series of nonpeptide vasopressin V2 receptor antagonists. It has been demonstrated that the 1-[4-(benzoylamino)benzoyl]-2,3,4,5-1H-benzazepines and 1-[4-(benzoylamino)benzoyl]-2,3,4,5-1H-1,5-benzodiazepines show a high affinity for V2 (and V1a) receptors. Among the 1-[4-(benzoylamino)benzoyl]-2,3,4,5-1H-benzazepine series, compounds with an alkylamino group on the benzazepine
本文介绍了一系列新型的非肽加压素V2受体拮抗剂。已经证明1- [4-(苯甲酰基氨基)苯甲酰基] -2,3,4,5-1H-苯并ze庚因和1- [4-(苯甲酰基氨基)苯甲酰基] -2,3,4,5-1H- 1,5-苯二氮卓类药物对V2(和V1a)受体具有很高的亲和力。在1- [4-(苯甲酰基氨基)苯甲酰基] -2,3,4,5-1H-苯并ze庚因系列中,已证明在苯并ze庚因环上具有烷基氨基的化合物具有口服活性。末端苯甲酰基环邻位的亲脂性基团对于高V2受体亲和力和口服活性均很重要。基于这些有利的性质,已经开始将31b用作口服和静脉内水族药物的临床试验。